Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 19.7% in March

Jasper Therapeutics, Inc. (NASDAQ:JSPR) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 1,670,000 shares, a decrease of 19.7% from the February 28th total of 2,080,000 shares. Based on an average daily volume of 526,700 shares, the short-interest ratio is currently 3.2 days. Approximately 14.1% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several research firms have recently commented on JSPR. Royal Bank of Canada reduced their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price for the company. UBS Group initiated coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $38.00 price target on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday, January 6th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $62.50.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $4.14 on Wednesday. Jasper Therapeutics has a 1 year low of $4.11 and a 1 year high of $30.70. The firm’s 50-day moving average is $5.63 and its 200-day moving average is $14.47. The company has a market cap of $62.19 million, a P/E ratio of -0.87 and a beta of 2.23.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). As a group, sell-side analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC acquired a new stake in Jasper Therapeutics in the third quarter worth $722,000. BNP Paribas Financial Markets grew its position in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares during the last quarter. MetLife Investment Management LLC lifted its position in Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares during the last quarter. Verition Fund Management LLC bought a new stake in Jasper Therapeutics in the 3rd quarter valued at about $477,000. Finally, Samsara BioCapital LLC boosted its stake in Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after purchasing an additional 59,642 shares during the period. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.